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ABSTRACT
Introduction: Management of Lennox–Gastaut
syndrome (LGS) in adulthood can be
particularly challenging. Published reports
describing the use of rufinamide specifically in
adult patients with LGS are scarce. A post hoc
subgroup analysis of data from a phase III trial
was conducted to investigate the efficacy and
safety/tolerability of rufinamide in adults with
LGS.
Methods: A randomized, double-blind,
placebo-controlled trial was conducted in
patients with LGS, aged 4 years and above.
During an 84-day, double-blind treatment
period, patients received either adjunctive
rufinamide therapy or placebo. Efficacy and
safety/tolerability were assessed in a post hoc
subgroup analysis of adult patients (C18 years).
Efficacy was assessed as change from baseline in
28-day seizure frequency, 50% responder rate,
and seizure freedom rate; each calculated for
total seizures and drop attacks.
Safety/tolerability assessments included the
evaluation of adverse events (AEs).
Results: Thirty-one adults aged 18–37 years
with LGS received treatment with either
rufinamide (n = 21) or placebo (n = 10). Three
patients in the rufinamide group did not
complete the trial. The median change from
baseline in seizure frequency was -31.5% for
rufinamide versus ?22.1% for placebo
(P = 0.008) for all seizures and -54.9% versus
?21.7% (P = 0.002) for drop attacks. Responder
rates were 33.3% for rufinamide versus 0% for
placebo (P = 0.066) for all seizures and 57.1%
versus 10.0% (P = 0.020) for drop attacks. No
patient achieved freedom from all seizures but
two rufinamide-treated patients (9.5%) became
free of drop attacks. Overall, 71.4% of patients
treated with rufinamide and 60.0% of patients
treated with placebo experienced AEs; most
commonly, somnolence (33.3% vs. 20.0%) and
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vomiting (19.0% vs. 0%). Most AEs were of mild
or moderate intensity.
Conclusion: Rufinamide demonstrated
favorable efficacy and was generally well
tolerated when used as adjunctive treatment
for adults with LGS.
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INTRODUCTION
Lennox–Gastaut syndrome (LGS) is a severe,
chronic, epileptic encephalopathy that is
associated with considerable morbidity and
mortality [1, 2]. It is characterized by a triad of
symptoms: multiple seizure types, abnormal
electroencephalogram (EEG) features with slow
spike-wave discharges, and cognitive
impairment [1]. To date, only a few
antiepileptic drugs (AEDs) have demonstrated
efficacy against the multiple seizure types
associated with LGS [3].
Rufinamide is a triazole derivative,
structurally unrelated to other AEDs [4], which
is approved for adjunctive treatment of seizures
associated with LGS in patients aged C4 years
[5–7]. The efficacy and safety/tolerability of
rufinamide in this setting were established in a
phase III, international, multicenter,
randomized, double-blind, placebo-controlled
trial, in which 138 LGS patients, aged
4–37 years, were randomized to receive
adjunctive therapy with either rufinamide or
placebo [3].
Although LGS typically begins during
childhood, it frequently persists through
adolescence and into adulthood, and may
also, rarely, have late onset during adolescence
or adulthood [2]. Diagnosis of LGS is
complicated by the fact that the seizure types
and other features by which it is defined and
characterized evolve and change over time, and,
in adulthood, the way in which it presents may
not be consistent with the typical features
associated with early-onset LGS [2].
The objective of this study was to investigate
further the efficacy and safety/tolerability of
rufinamide in adults with LGS.
METHODS
Study Design
A post hoc subgroup analysis was conducted of
adult data (aged 18 years and above) from a
phase III, randomized, double-blind,
placebo-controlled trial, conducted between
March 1998 and September 2000 [3]. The trial
comprised a 28-day baseline period, followed by
an 84-day treatment period (14-day titration
plus 70-day maintenance). Rufinamide
(Inovelon, Eisai Ltd; Banzel, Eisai Inc.) was
administered as adjunctive therapy to one to
three concomitant AEDs, and initiated and
titrated according to approved
recommendations [6, 7]. The dose
administered at the end of the titration period
was used for the entire maintenance period and
study visits were conducted on Days 0, 7, 14, 28,
56, and 84 after randomization.
Study Population
The overall trial population included patients
aged C4 years with a history of multiple seizure
types, including atypical absence seizures and
drop attacks (tonic–atonic or astatic seizures).
Patients were required to have C90 seizures in
the month prior to the baseline period, an EEG
within 6 months of study entry demonstrating a
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pattern of slow spike-and-wave complexes
(\2.5 Hz), and a computed tomography or
magnetic resonance imaging scan confirming
the absence of a progressive lesion. They were
also required to be on a fixed-dose regimen of
one to three concomitant AEDs during the
baseline period and to provide written
informed consent. Patients were excluded if
they had a correctable seizure etiology (such as
active infection), history of generalized
tonic–clonic status epilepticus within 30 days
before baseline, or history of any
non-neurological medical condition; and if
they were pregnant or failed to use adequate
contraception.
Study Assessments
Efficacy was assessed as change from baseline in
28-day seizure frequency (i.e., number of
seizures per 28 days), responder rate (response
defined as C50% seizure frequency reduction
from baseline), and seizure freedom rate; each
calculated for total seizures and drop attacks
(tonic–atonic seizures). Safety/tolerability
assessments included the evaluation of adverse
events (AEs), physical/neurological
examinations, vital signs, laboratory
parameters, and electrocardiogram (ECG)
recordings [3]. AEs were defined as any
undesirable effects experienced by the patient,
irrespective of relation to the study drug. AEs
were considered serious if they were fatal or
life-threatening, permanently disabling, or
required inpatient or prolonged hospitalization.
Statistical Methodology
A post hoc subgroup analysis of the adult data
was conducted. Efficacy analysis was
performed for the intention-to-treat
population, defined as all randomized
patients who received the double-blind study
drug. All 84 days of double-blind treatment
(i.e., titration period plus maintenance period)
were included in the intention-to-treat
analysis. Median change from baseline in
28-day frequency was compared between
groups using the Wilcoxon Rank Sum Test
(unadjusted). Responder and seizure freedom
rates were analyzed using frequency analysis.
Responder rates were compared between
groups using Fisher’s Exact Test. All statistical
tests were performed using SAS version 9 (SAS
Institute Inc., Cary, NC, USA). The safety
population comprised all patients who
received at least one dose of study drug.
Ethics
All procedures were conducted in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all




The trial included a total of 31 adult patients,
aged 18–37 years, randomized to treatment
with rufinamide (n = 21) or placebo (n = 10).
Overall, 18/21 (85.7%) patients in the
rufinamide group and 10/10 (100%) patients
in the placebo group completed the trial.
Reasons for discontinuation in the
rufinamide group were AEs (anorexia,
somnolence, and vomiting; n = 1), lack of
efficacy (n = 1), and withdrawal of consent
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(n = 1). The mean age of the adult patients
was 25.2 and 29.3 years in the rufinamide and
placebo groups, respectively (Table 1). The
most frequently used concomitant AEDs at
baseline were lamotrigine, valproate, and
phenytoin.
Table 1 Baseline characteristics of adult patients with LGS (n = 31)
Characteristics Rufinamide (n5 21) Placebo (n5 10)
Sex, n (%)
Male 15 (71.4) 5 (50.0)
Female 6 (28.6) 5 (50.0)
Ethnicity, n (%)
Caucasian 20 (95.2) 9 (90.0)
Black 0 (0.0) 1 (10.0)
Asian 1 (4.8) 0 (0.0)
Age, years
Mean (SD) 25.2 (4.7) 29.3 (7.1)
Median (range) 25.0 (18–35) 31.5 (18–37)
Time since LGS diagnosis, years
Mean (SD) 18.5 (8.9) 25.5 (8.1)
Median (range) 21 (0–33) 28.5 (8–34)
Number of concomitant AEDs, n (%)
2 10 (47.6) 4 (40.0)
3 11 (52.4) 6 (60.0)
Most frequently used concomitant AEDs (C5% patients), n (%)
Lamotrigine 10 (47.6) 4 (40.0)
Valproate 9 (42.9) 9 (90.0)
Phenytoin 5 (23.8) 4 (40.0)
Topiramate 6 (28.6) 1 (10.0)
Carbamazepine 5 (23.8) 2 (20.0)
Clonazepam 4 (19.0) 3 (30.0)
Phenobarbital 3 (14.3) 0 (0.0)
Clobazam 2 (9.5) 0 (0.0)
Gabapentin 2 (9.5) 0 (0.0)
Vigabatrin 1 (4.8) 1 (10.0)
Oxcarbazepine 0 (0.0) 2 (20.0)
AED antiepileptic drug, LGS Lennox–Gastaut syndrome, SD standard deviation
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Rufinamide Treatment
The mean (standard deviation [SD]) maximum
dose of rufinamide administered to the adult
patients during the trial was 2476.2
(594.9) mg/day (median, 2400 mg/day; range,
1600–3200 mg/day). The mean (SD) final
rufinamide dose administered was 2171.4
(886.1) mg/day (median, 2400 mg/day; range,
200–3200 mg/day).
Efficacy
The median change from baseline in 28-day
frequency of total seizures was -31.5% (mean,
-26.9%; SD, 52.5%; range, -92.3 to 136.5%)
with rufinamide versus ?22.1% (mean, 67.5%;
SD, 173.1%; range, -36.6 to 550.6%) with
placebo (P = 0.008; Fig. 1a). The median
change from baseline in 28-day frequency of
drop attacks was -54.9% (mean, -19.0%; SD,
111.7%; range, -55.9 to 406.7%) with
rufinamide versus ?21.7% (mean, 136.2%; SD,
255.2%; range, -55.9 to 709.6%) with placebo
(P = 0.002; Fig. 1a).
Responder rates for total seizures were 33.3%
with rufinamide versus 0% with placebo
(P = 0.066; Fig. 1b). Responder rates for drop
attacks were 57.1% with rufinamide versus
10.0% with placebo (P = 0.020; Fig. 1b). No
patient achieved seizure freedom (i.e., freedom
from all seizures), but two patients treated with
rufinamide (9.5%) became free of drop attacks
during the trial.
Safety/Tolerability
Overall, 15/21 (71.4%) patients treated with
rufinamide and six of 10 (60.0%) patients treated
with placebo experienced AEs (Table 2). The most
frequently reported AEs were somnolence and
vomiting (Table 2). The majority of AEs were of
mild or moderate intensity. Three rufinamide
patients experienced severe AEs (somnolence,
somnolence and hostility, and constipation). No
patient experienced a serious AE. One patient
experienced status epilepticus while receiving
rufinamide 1400 mg/day. This patient was later
withdrawn from the study due to other AEs
(anorexia, somnolence, and vomiting).
Rufinamide treatment was not associated with
clinically significant changes in vital signs,
physical examinations, ECG recordings, or
laboratory tests [3].
DISCUSSION
In this post hoc subgroup analysis, rufinamide
demonstrated favorable efficacy when used as
adjunctive treatment for adults with LGS.
Rufinamide treatment significantly reduced
the frequency of total seizures compared with
placebo. Rufinamide was particularly efficacious
in reducing the frequency of drop attacks,
resulting in a median reduction from baseline
in 28-day frequency of 55% and a responder
rate of 57%, with two patients becoming free of
drop attacks during the trial. These findings
therefore support recent guidelines suggesting
that rufinamide might be preferable to other
AEDs as a second-line treatment for LGS when
drop attacks are frequent [8]. The findings are
also in line with a study demonstrating the
long-term effectiveness of rufinamide for the
treatment of pharmacoresistant
myoclonic-atonic seizures in children with
Doose syndrome [9].
Rufinamide treatment was generally well
tolerated; the most frequently reported AEs
(somnolence and vomiting) were the same as
those most frequently reported for the overall
population in the original trial [3]. There were
no serious AEs and only one patient
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discontinued due to AEs associated with
rufinamide treatment. It should be noted that
published reports suggest that, in clinical
practice, where treatment is individualized, a
‘lower and slower’ dosing strategy tends to be
adopted, which does not appear to compromise
rufinamide’s efficacy, but may provide
improvements in tolerability [5].
Fig. 1 a Median per-
centage changes from
baseline in 28-day fre-
quency and
b responder rates for




drome (n = 31).
Response was defined
as C50% seizure fre-
quency reduction
from baseline
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An acknowledged limitation of this analysis
is that it was conducted in a relatively small
subgroup of adult patients with LGS. Other
clinical trials and clinical practice studies have
demonstrated the efficacy and
safety/tolerability of adjunctive rufinamide
treatment for LGS in patient populations that
have included a limited number of adult
patients as well as pediatric patients [10–18].
However, published reports describing the use
of rufinamide specifically in adult patients with
LGS are scarce. In a single-center study
conducted in France, clinically significant
weight loss (C7% decrease from baseline) was
reported in seven of 15 consecutive adult
patients treated with adjunctive rufinamide,
five of whom had LGS [19]. The authors
concluded that a lower starting dose and
slower titration rate might help minimize the
possibility of weight loss, although it was
acknowledged that this requires confirmation
[19]. Weight loss is known to be a common AE
with rufinamide treatment [6]. In the current
analysis, decreased weight was reported as an AE
for one rufinamide-treated patient. In addition,
AEs of decreased appetite and anorexia were
reported for three and two rufinamide-treated
patients, respectively. In a single-center study
conducted in Germany, the mean QT interval of
19 consecutive adult patients treated with
adjunctive rufinamide, nine of whom had
LGS, shortened significantly with rufinamide
treatment [20], consistent with rufinamide’s
known safety profile [6]. However, during a
mean follow-up of 3.6 years, no symptomatic
cardiac arrhythmias occurred and no associated
AEs were reported [20]. In the present analysis,
no AEs associated with QT interval or other ECG
parameters were reported. Prescribing
guidelines recommend that clinical judgment
be used when assessing whether to prescribe
rufinamide to patients at risk from further
shortening of their QTc interval [6].
Although beyond the scope of the present
analysis, given the limited number of adult
patients, in future studies it will be important to
Table 2 Summary of AEs reported by adult patients with Lennox–Gastaut syndrome (n = 31)
Rufinamide (n5 21) Placebo (n5 10)
Patients with any AE, n (%) 15 (71.4) 6 (60.0)
Patients with any serious AE, n (%) 0 (0.0) 0 (0.0)
Patients with AEs leading to discontinuation, n (%) 1 (4.8) 0 (0.0)
AEs reported by[10% patients in either group, n (%)
Somnolence 7 (33.3) 2 (20.0)
Vomiting 4 (19.0) 0 (0.0)
Ecchymosis 3 (14.3) 1 (10.0)
Fatigue 3 (14.3) 0 (0.0)
Ataxia 3 (14.3) 0 (0.0)
Decreased appetite 3 (14.3) 0 (0.0)
Headache 2 (9.5) 2 (20.0)
Pyrexia 0 (0.0) 2 (20.0)
AE adverse event
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establish the extent to which the clinical and
EEG features of LGS in adulthood differ from
those in childhood. A recent retrospective
analysis of the long-term prognosis of
68 patients with LGS found that the
characteristic EEG features of LGS (diffuse slow
spike-wave and generalized paroxysmal fast
activity) ceased in half of the patients over a
mean follow-up duration of approximately
19 years [21]. Such findings might therefore
support a need to broaden or adapt the
diagnostic criteria for LGS in adulthood, to
ensure that patients receive the most
appropriate treatment.
CONCLUSION
This analysis demonstrated that rufinamide was
efficacious and generally well tolerated when
used as an adjunctive treatment in adult
patients with LGS. Further studies are needed
to confirm its utility in this setting.
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